☆ 4.5 Article

People Diagnosed with Myasthenia Gravis have Lower health-related quality of life and Need More Medical and Caregiver Help in Comparison to the General Population: Analysis of Two Observational Studies

ADVANCES IN THERAPY (2023)

Related references

Note: Only part of the references are listed.

Article Clinical Neurology

Efgartigimod improved health-related quality of life in generalized myasthenia gravis: results from a randomized, double-blind, placebo-controlled, phase 3 study (ADAPT)

Francesco Sacca et al.

Summary: Patients with myasthenia gravis (MG) who have poorly controlled symptoms experience significant disease and health-related quality-of-life (HRQoL) burdens. HRQoL measures such as the MG-QOL15r and EQ-5D-5L are essential for evaluating the clinical benefit of therapeutic interventions. The ADAPT study demonstrated that efgartigimod, a novel neonatal Fc receptor inhibitor, improved MG-specific clinical scale scores and HRQoL measures.

JOURNAL OF NEUROLOGY (2023)

Add to Collection

Article Medicine, Research & Experimental

Association Between Myasthenia Gravis-Activities of Daily Living (MG-ADL) and EQ-5D-5L Utility Values: The Additional Effect of Efgartigimod on Utilities

Sarah Dewilde et al.

Summary: For patients with generalized myasthenia gravis (gMG), the association between symptom severity (measured with MG-ADL) and utility values is unknown. This study analyzed data from the ADAPT trial and found a significant association between MG-ADL scores and utility values in gMG patients. Furthermore, treatment with efgartigimod showed significant improvements in both symptoms and quality of life.

ADVANCES IN THERAPY (2023)

Add to Collection

Article Biotechnology & Applied Microbiology

Ravulizumab for the treatment of myasthenia gravis

Fiammetta Vanoli et al.

Summary: Myasthenia gravis (MG) is an autoimmune disorder affecting the neuromuscular junction. Current treatments rely on nonselective immunosuppression, but have significant side effects and some patients are refractory. Ravulizumab, a selective immunosuppressive drug, has shown promising results in a randomized-controlled study (CHAMPION MG).

EXPERT OPINION ON BIOLOGICAL THERAPY (2023)

Add to Collection

Article Clinical Neurology

Burden of disease in myasthenia gravis: taking the patient's perspective

Sophie Lehnerer et al.

Summary: Patients with myasthenia gravis (MG) have lower health-related quality of life (HRQoL) compared to the general population, with economic, social, and emotional aspects contributing to the burden of the disease. Factors associated with lower HRQoL in MG patients include female gender, older age, low income, lack of partner, limited daily activities, symptoms of depression, anxiety, fatigue, and perceived low social support.

JOURNAL OF NEUROLOGY (2022)

Add to Collection

Article Public, Environmental & Occupational Health

An EQ-5D-5L value set for Italy using videoconferencing interviews and feasibility of a new mode of administration

Aureliano Paolo Finch et al.

Summary: This study tested the feasibility of using videoconferencing for preference collection and derived an EQ5D-5L value set for Italy. The pilot demonstrated the technical, organizational, and protocol feasibility of videoconferencing interviews. Data models were chosen and the values for health states were determined. Videoconferencing was deemed as a viable mode for conducting valuation interviews.

SOCIAL SCIENCE & MEDICINE (2022)

Add to Collection

Review Clinical Neurology

The humanistic burden of myasthenia gravis: A systematic literature review

Deborah Gelinas et al.

Summary: This systematic literature review aimed to explore the humanistic burden of myasthenia gravis (MG) on patients and caregivers in terms of psychological symptoms and health-related quality of life (HRQoL). The review found that patients with MG had worse HRQoL compared to the general population. Studies on psychological symptoms showed that more severe symptoms and longer hospitalization days were associated with worse depression and anxiety, while fatigue and sleep improved with disease remission and/or improvement.

JOURNAL OF THE NEUROLOGICAL SCIENCES (2022)

Add to Collection

Article Medicine, General & Internal

Quality of Life in Myasthenia Gravis and Correlation of MG-QOL15 with Other Functional Scales

Laura Diez Porras et al.

Summary: This study aimed to evaluate the impact of intensive treatment on the quality of life of patients with myasthenia gravis and identify the demographic and clinical features that influence quality of life. The results showed that quality of life significantly improved after 4 and 6 weeks of treatment. Additionally, the MG-QOL15 questionnaire was found to be correlated with other evaluation scales.

JOURNAL OF CLINICAL MEDICINE (2022)

Add to Collection

Article Economics

An EQ-5D-5L Value Set for Belgium

Nicolas Bouckaert et al.

Summary: This study aimed to establish a Belgian EQ-5D-5L value set based on the preferences of the adult Belgian general population. The preferred model specification was a hybrid multiplicative eight-coefficient model with intercept random effects and correction for heteroskedasticity. The study provides opportunities for future clinical and economic evaluations, measurement of patient-reported outcomes, and population health assessments.

PHARMACOECONOMICS-OPEN (2022)

Add to Collection

Article Clinical Neurology

Social, professional and neuropsychiatric outcomes in patients with myasthenia gravis

Bruno Kusznir Vitturi et al.

Summary: Patients with MG experience social, professional, and mental disadvantages, with many facing unemployment or reduced income after diagnosis, only a small percentage receiving financial support and satisfactory social support, and a high prevalence of neuropsychiatric symptoms.

NEUROLOGICAL SCIENCES (2021)

Add to Collection

Article Health Care Sciences & Services

Obtaining EQ-5D-5L utilities from the disease specific quality of life Alzheimer's disease scale: development and results from a mapping study

Ines Rombach et al.

Summary: A new mapping algorithm was reported to obtain EQ-5D indices when only QoL-AD data are available. The response model using multinomial regression including age and sex performed best in both estimation and independent datasets. This recommended mapping algorithm allows researchers to estimate EQ-5D values from QoL-AD data for cost-utility analyses.

QUALITY OF LIFE RESEARCH (2021)

Add to Collection

Article Health Care Sciences & Services

Assessing the Appropriateness of the EQ-5D for Duchenne Muscular Dystrophy: A Patient-Centered Study

Norah L. Crossnohere et al.

Summary: This study assessed the appropriateness of the EQ-5D measure in patients and caregivers affected by Duchenne muscular dystrophy. The results showed that despite concerns, the EQ-5D was found to be suitable for assessing health status in Duchenne. Participants felt that the EQ-5D accurately measured real health status, was easy to understand, and answer.

MEDICAL DECISION MAKING (2021)

Add to Collection

Meeting Abstract Clinical Neurology

Estimation of myasthenia gravis prevalence in Italy using realworld data

Giovanni Antonini et al.

JOURNAL OF THE NEUROLOGICAL SCIENCES (2021)

Add to Collection

Editorial Material Clinical Neurology

Myasthenia gravis: do not forget the patient perspective

Nils Erik Gilhus et al.

NEUROMUSCULAR DISORDERS (2021)

Add to Collection

Article Economics

The Danish EQ-5D-5L Value Set: A Hybrid Model Using cTTO and DCE Data

Cathrine Elgaard Jensen et al.

Summary: The study developed the first Danish value set for the EQ-5D-5L based on interviews with a representative sample of the Danish adult population. The chosen hybrid model combining cTTO and DCE data provided consistent results for modelling the final Danish value set.

APPLIED HEALTH ECONOMICS AND HEALTH POLICY (2021)

Add to Collection

Article Clinical Neurology

Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT) : a multicentre, randomised, placebo-controlled, phase 3 trial

James F. Jr Jr Howard et al.

Summary: The study evaluated the safety and efficacy of efgartigimod in patients with generalised myasthenia gravis, showing that it was well tolerated and efficacious. The unique feature of individualized dosing based on clinical response in the study will provide further insights into clinical practice with longer term data from the ongoing open-label extension.

LANCET NEUROLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Patient-reportedimpact of myasthenia gravis in the real world: protocol for a digital observational study (MyRealWorld MG)

Sonia Berrih-Aknin et al.

Summary: This study examines the impact of MG in the real world from the patient perspective. It is a 2-year prospective, observational, digital, longitudinal study of adults with MG from various countries. Study results will be disseminated through conference presentations, journal publications, email, social media, and in-application communication.

BMJ OPEN (2021)

Add to Collection

Review Medicine, General & Internal

Myasthenia Gravis: Epidemiology, Pathophysiology and Clinical Manifestations

Laura Dresser et al.

Summary: Myasthenia gravis (MG) is an autoimmune neurological disorder characterized by defective transmission at the neuromuscular junction. The core clinical manifestation is fatigable muscle weakness, which may vary according to the type of autoantibody and whether a thymoma is present.

JOURNAL OF CLINICAL MEDICINE (2021)

Add to Collection

Article Public, Environmental & Occupational Health

Health-related quality of life of multiple sclerosis patients: a European multi-country study

Laurenske A. Visser et al.

Summary: This study investigated the health-related quality of life of multiple sclerosis patients in several countries, revealing differences in HRQOL among them. Disability status and primary progressive MS were found to be common predictors of HRQOL.

ARCHIVES OF PUBLIC HEALTH (2021)

Add to Collection

Article Economics

A French Value Set for the EQ-5D-5L

Luiz Flavio Andrade et al.

PHARMACOECONOMICS (2020)

Add to Collection

Article Clinical Neurology

Exploring outcomes and characteristics of myasthenia gravis: Rationale, aims and design of registry - The EXPLORE-MG registry

Rahul Anil et al.

JOURNAL OF THE NEUROLOGICAL SCIENCES (2020)

Add to Collection

Article Genetics & Heredity

Costs of illness in amyotrophic lateral sclerosis (ALS): a cross-sectional survey in Germany

Erik Schoenfelder et al.

ORPHANET JOURNAL OF RARE DISEASES (2020)

Add to Collection

Article Clinical Neurology

Determinants of Quality of Life in Myasthenia Gravis Patients

Piotr Szczudlik et al.

FRONTIERS IN NEUROLOGY (2020)

Add to Collection

Review Clinical Neurology

Outcome Measures in Clinical Trials of Patients With Myasthenia Gravis

Jan Lykke Scheel Thomsen et al.

FRONTIERS IN NEUROLOGY (2020)

Add to Collection

Review Medicine, General & Internal

A Review of Psychiatric Comorbidity in Myasthenia Gravis

Christina Law et al.

CUREUS JOURNAL OF MEDICAL SCIENCE (2020)

Add to Collection

Article Health Care Sciences & Services

A head-to-head comparison of EQ-5D-5L and SF-6D in Chinese patients with low back pain

Ziping Ye et al.

HEALTH AND QUALITY OF LIFE OUTCOMES (2019)

Add to Collection

Article Economics

United States Valuation of EQ-5D-5L Health States Using an International Protocol

A. Simon Pickard et al.

VALUE IN HEALTH (2019)

Add to Collection

Review Health Care Sciences & Services

A comprehensive catalogue of EQ-5D scores in chronic disease: results of a systematic review

Lisa Van Wilder et al.

QUALITY OF LIFE RESEARCH (2019)

Add to Collection

Article Clinical Neurology

Cross-sectional analysis of the Myasthenia Gravis Patient Registry: Disability and treatment

Gary Cutter et al.

MUSCLE & NERVE (2019)

Add to Collection

Article Clinical Neurology

EQ-5D-5L and SF-6D health utility index scores in patients with myasthenia gravis

C. Barnett et al.

EUROPEAN JOURNAL OF NEUROLOGY (2019)

Add to Collection

Article Economics

Population norms for the EQ-5D-3L: a cross-country analysis of population surveys for 20 countries

M. F. Janssen et al.

EUROPEAN JOURNAL OF HEALTH ECONOMICS (2019)

Add to Collection

Article Economics

German Value Set for the EQ-5D-5L

Kristina Ludwig et al.

PHARMACOECONOMICS (2018)

Add to Collection

Article Economics

Handling Data Quality Issues to Estimate the Spanish EQ-5D-5L Value Set Using a Hybrid Interval Regression Approach

Juan M. Ramos-Goni et al.

VALUE IN HEALTH (2018)

Add to Collection

Article Economics

Societal costs of multiple sclerosis in Ireland

Peter Carney et al.

JOURNAL OF MEDICAL ECONOMICS (2018)

Add to Collection

Article Clinical Neurology

The disease burden of Multiple Sclerosis from the individual and population perspective: Which symptoms matter most?

Laura Barin et al.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2018)

Add to Collection

Article Clinical Neurology

Quality of life among multiple sclerosis patients in Saudi Arabia

Hussein A. Algahtani et al.

NEUROSCIENCES (2017)

Add to Collection

Article Economics

The burden of multiple sclerosis in Japan

Chiyoko Nohara et al.

JOURNAL OF MEDICAL ECONOMICS (2017)

Add to Collection

Article Clinical Neurology

Labour market participation and sick leave among patients diagnosed with myasthenia gravis in Denmark 1997-2011: a Danish nationwide cohort study

Asger Frost et al.

BMC NEUROLOGY (2016)

Add to Collection

Article Economics

Comparison of Value Set Based on DCE and/or TTO Data: Scoring for EQ-5D-5L Health States in Japan

Takeru Shiroiwa et al.

VALUE IN HEALTH (2016)

Add to Collection

Article Economics

Dutch Tariff for the Five-Level Version of EQ-5D

Matthijs M. Versteegh et al.

VALUE IN HEALTH (2016)

Add to Collection

Article Health Care Sciences & Services

An up-date on health-related quality of life in myasthenia gravis -results from population based cohorts

M. I. Boldingh et al.

HEALTH AND QUALITY OF LIFE OUTCOMES (2015)

Add to Collection

Article Clinical Neurology

Convergent validation of EQ-5D-5L in patients with Parkinson's disease

Alonso Alvarado-Bolanos et al.

JOURNAL OF THE NEUROLOGICAL SCIENCES (2015)

Add to Collection

Article Health Care Sciences & Services

Validation and comparison of 15-D and EQ-5D-5L instruments in a Spanish Parkinson's disease population sample

Miguel Angel Garcia-Gordillo et al.

QUALITY OF LIFE RESEARCH (2014)

Add to Collection

Article Clinical Neurology

Relating health-related Quality of Life to disability progression in multiple sclerosis, using the 5-level EQ-5D

Emer Fogarty et al.

MULTIPLE SCLEROSIS JOURNAL (2013)

Add to Collection

Article Geriatrics & Gerontology

Patient and proxy measurement of quality of life among general hospital in-patients with dementia

Bart D. Sheehan et al.

AGING & MENTAL HEALTH (2012)

Add to Collection

Article Economics

Interim Scoring for the EQ-5D-5L: Mapping the EQ-5D-5L to EQ-5D-3L Value Sets

Ben van Hout et al.

VALUE IN HEALTH (2012)

Add to Collection

Article Clinical Neurology

MG-ADL: STILL A RELEVANT OUTCOME MEASURE

Srikanth Muppidi et al.

MUSCLE & NERVE (2011)

Add to Collection

Article Health Care Sciences & Services

Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)

M. Herdman et al.

QUALITY OF LIFE RESEARCH (2011)

Add to Collection

Review Clinical Neurology

Myasthenic Crisis

Linda C. Wendell et al.

NEUROHOSPITALIST (2011)

Add to Collection

Article Clinical Neurology

Benefits from sustained-release pyridostigmine bromide in myasthenia gravis: Results of a prospective multicenter open-label trial

Joern Peter Sieb et al.

CLINICAL NEUROLOGY AND NEUROSURGERY (2010)

Add to Collection

Article Health Care Sciences & Services

Quality of life and life circumstances in German myasthenia gravis patients

Sabine Twork et al.

HEALTH AND QUALITY OF LIFE OUTCOMES (2010)

Add to Collection

Article Clinical Neurology

Health-related quality of life in ALS, myasthenia gravis and facioscapulohumeral muscular dystrophy

Yaroslav Winter et al.

JOURNAL OF NEUROLOGY (2010)

Add to Collection

Article Clinical Neurology

Development of generalized disease at 2 years in patients with ocular myrasthenia gravis

MJ Kupersmith et al.

ARCHIVES OF NEUROLOGY (2003)

Add to Collection

Review Health Care Sciences & Services

Comparative responsiveness of generic and specific quality-of-life instruments

S Wiebe et al.

JOURNAL OF CLINICAL EPIDEMIOLOGY (2003)

Add to Collection

Article Health Care Sciences & Services

Multiattribute and single-attribute utility functions for the health utilities index mark 3 system

D Feeny et al.

MEDICAL CARE (2002)

Add to Collection

Article Clinical Neurology

Patients' health-related quality of life and utilities associated with different stages of amyotrophic lateral sclerosis

GM Kiebert et al.

JOURNAL OF THE NEUROLOGICAL SCIENCES (2001)

Add to Collection

Article Clinical Neurology

The EQ-5D - a generic quality of life measure - is a useful instrument to measure quality of life in patients with Parkinson's disease

A Schrag et al.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2000)

Add to Collection

© Peeref 2019-2024. All rights reserved.